The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment, prevention, or reduction of incidence of a disease or disorder in a human in need thereof, the method comprising administering to the human a liquid NORS comprised of at least one nitrite compound at a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO.

A system for deliverying a therapeutic amount of nitric oxide can include a reservoir assembly, a gas supply, and a delivery conduit including a first cartridge, wherein the first cartridge can include a surface-activated material saturated with an aqueous solution of a reducing agent.

A system for deliverying a therapeutic amount of nitric oxide can include a reservoir assembly, a gas supply, and a delivery conduit including a first cartridge, wherein the first cartridge can include a surface-activated material saturated with an aqueous solution of a reducing agent.

Described herein are nitric oxide releasing materials, methods of making nitric oxide releasing materials, and devices including nitric oxide releasing materials. The nitric oxide releasing material includes a polymer matrix having a plurality of polysiloxanes and nitric oxide-donating crosslinking moieties that covalently crosslink the polysiloxanes. Blood clotting or adhesion of a bio-material to a surface, as well as biofilm formation can be prevented using the methods and materials described.

Systems and methods for nitric oxide (NO) generation systems are provided. In some embodiments, an NO generation system comprises at least one pair of electrodes configured to generate a product gas containing NO from a flow of a reactant gas. The electrodes have elongated surfaces such that a plasma produced is carried by the flow of the reactant gas and glides along the elongated surfaces from a first end towards a second end of the electrode pair. A controller is configured to regulate the amount of NO in the product gas by the at least one pair of electrodes using one or more parameters as an input to the controller. The one or more parameters include information from a plurality of sensors configured to collect information relating to at least one of the reactant gas, the product gas, and a medical gas into which the product gas flows.

A moisture or hydrating liquid activatable solid formulation for nitric oxide (NO) generation includes a nitrite source; a copper (I) or copper (II) catalyst; an NO generation accelerant; and a solid pH buffer. The nitrite source is to generate NO when exposed to an effective amount of moisture or a hydrating liquid. The pH buffer is present in an amount sufficient to render a pH of the moisture or hydrating liquid activatable solid formulation from greater than 4 to about 9.0.

A moisture or hydrating liquid activatable solid formulation for nitric oxide (NO) generation includes a nitrite source; a copper (I) or copper (II) catalyst; an NO generation accelerant; and a solid pH buffer. The nitrite source is to generate NO when exposed to an effective amount of moisture or a hydrating liquid. The pH buffer is present in an amount sufficient to render a pH of the moisture or hydrating liquid activatable solid formulation from greater than 4 to about 9.0.

Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal or based on a synchronous parameter of the mammal's respiratory cycle. Varying therapeutic profiles may be used for the delivery of gaseous nitric oxide depending on the severity of the excess mucus accumulation. Parameters for the therapeutic profiles may include flow rate of nitric oxide containing gas, duration of administration of nitric oxide containing gas, number of breaths for which nitric oxide containing gas is to be administered, and concentrations of therapeutic NO delivered to the airways.

A nitric oxide delivery system can include a cassette which is a single use disposable component used to store liquid N.sub.2O.sub.4 activate upon operator demand, convert N.sub.2O.sub.4 to NO.sub.2 via a heating element(s) controlled by a console to deliver NO.sub.2 at a controlled flow rate, direct concentrated NO.sub.2 to a contained pair of conversion cartridges and exhaust NO gas to the console for delivery to the patient.

A nitric oxide delivery system can include a cassette which is a single use disposable component used to store liquid N.sub.2O.sub.4 activate upon operator demand, convert N.sub.2O.sub.4 to NO.sub.2 via a heating element(s) controlled by a console to deliver NO.sub.2 at a controlled flow rate, direct concentrated NO.sub.2 to a contained pair of conversion cartridges and exhaust NO gas to the console for delivery to the patient.